Cardiogen is a Khavinson-developed tetrapeptide investigated for its role in cardiac muscle regulation and protection. Users typically run doses ranging from 1 mg to 5 mg daily, though most reports do not specify a consistent timing or cycling schedule. The primary tradeoff for a reader to consider is that the evidence base for this peptide is significantly thinner than the current discourse suggests, as most exploratory indications lack published results and all human use remains off-label. Because community reporting is extremely limited, there is currently no data available regarding side effects or tolerability profiles for this substance.
Data last updated
Measured on 4 of 6 axes
Evidence shape
Human evidence for Cardiogen is limited — pilot studies, withdrawn trials, or completed trials without posted results. Off-label / exploratory data exists for 1 additional indication (Radiation Exposure).
Efficacy signal
Completed studies are present, but primary-endpoint pass/fail classification is not yet clean enough to score. These are the currently projected indication-level signals.
Radiation Exposure
1 study · 1 completed
1 completed study row is present, but endpoint pass/fail classification is still pending.
Human evidence
Lower-tier support
Published literature
Standalone PubMed / Europe PMC publications matched to this peptide and deduped by identifier. Trial records and animal / in-vitro rows are surfaced above; these are the human-relevant papers behind them.
Source data
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
Symptom-relevant clinical or community evidence has not been captured for this peptide yet.
price offers can be sorted by column · 3 out-of-stock offers not shown
Some links are affiliate links. This never affects our rankings or inclusion.
How CARDIOGEN is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
No structured protocol details captured for this tier yet.
The single completed trial (NCT01424774) focused on determining radiation exposure from Sr-82/Sr-85, and available dosing information was not reliably extracted.
No structured protocol details captured for this tier yet.
In the community anecdotal reports, two of three users dose CARDIOGEN daily subcutaneously, with amounts ranging from 1 mg to 5 mg and a typical dose of 5 mg; no cycling was mentioned.